Total Hip Replacement Revision Rates Vary With Type of Material Used
By Elana Gotkine HealthDay Reporter
TUESDAY, Nov. 12, 2024 -- For patients undergoing primary total hip replacement (THR), the rate of revision varies by type of material used in the bearing surface, according to a study published online Nov. 7 in PLOS Medicine.
Michael R. Whitehouse, M.B., Ch.B., from the University of Bristol Medical School in the United Kingdom, and colleagues examined the revision rate of primary THR reported in the National Joint Registry. Data were analyzed for 1,026,481 primary THRs (monobloc: 378,979; modular: 647,502), of which 2 percent subsequently underwent a revision episode (monobloc: 7,381; modular: 13,488).
The researchers found that for monobloc implants, the all-cause risk for revision for monobloc acetabular implants was higher for patients with a cobalt chrome or stainless steel head and non-highly crosslinked polyethylene (HCLPE) cup versus those with a cobalt chrome head and HCLPE cup (hazard ratio at 10 years after surgery, 1.28 and 1.18, respectively). Patients with a delta ceramic head and HCLPE cup implant had a lower risk for revision at any postoperative period (hazard ratio at 10 years, 0.61). For modular implants, the all-cause risk for revision varied inconsistently for patients with modular acetabular implants compared with patients with a cobalt chrome head and HCLPE liner primary THR. The risk for revision was lower throughout the postoperative period for THRs with a delta ceramic or oxidized zirconium head and HCLPE liner (hazard ratios, 0.79 and 0.65, respectively).
"Further work is required to determine the association of implant bearing materials with the risk of rehospitalization, reoperation other than revision, mortality, and the cost-effectiveness of these materials," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Canagliflozin Tied to Reduction in HbA1c in Children, Teens With T2DM
WEDNESDAY, Aug. 6, 2025 -- Canagliflozin is associated with a clinically meaningful reduction in hemoglobin A1c (HbA1c) for children and adolescents with type 2 diabetes mellitus...
About One in Six Men With Grade Group 1 Prostate Cancer Has Intermediate-, High-Risk Disease
WEDNESDAY, Aug. 6, 2025 -- A proportion of men with grade group 1 (GG1) prostate cancer have a higher-risk disease than suggested by biopsy, according to a study published online...
Follow-Up on Blood-Based Colorectal Cancer Screening Results Is Low
TUESDAY, Aug. 5, 2025 -- Just under half of patients receiving an abnormal blood-based colorectal cancer screening test result receive a follow-up colonoscopy (FU-CY) within...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.